Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Stay committed, and give your body the time it needs to respond to the medication
A study from the Employee Benefit Research Institute estimates that expanding coverage of GLP-1 medications would drive premiums up between 5% and 14%, depending on adherence, cost-sharing, and eligibility details
500 Evalar Laboratory , , ,
Among these NAEs, exenatide accounted for 10,175 cases (35.14%), liraglutide for 3,686 cases (12.73%), lixisenatide for 256 cases (0.88%), dulaglutide for 6,034 cases (20.84%), semaglutide for 5,935 cases (20.50%), and tirzepatide for 2,867 cases (9.90%)
12
US$ 24.95
US$ 29.78
US$ 28.70
US$ 27.14
US$ 25.33
